World Health Organization Verdict is in: CBD is NOT ADDICTIVE OR TOXIC
The World Health Organization (WHO) has been examining possible uses of cannabidiol (CBD), a non psychoactive compound of cannabis marijuana.
Why should we care about what the WHO says? Who is the WHO?
Well, the WHO is a special agency that stems from the United Nations. The agency exists to deal with all matters that relate to the public health of the entire world. The WHO has played a major role in eradicating some diseases and keeping tabs on others. The WHO also helps to halt the spread of certain diseases. They also communicate important messages worldwide about all matters relating to health, from development to nutrition, job safety, substance abuse, sexual health, and more.
They are the leading authority on matters of health and wellness that are relevant to the world at large. That’s why their findings matter to so many people!
Their results are not likely to shock those who already understand the many potential benefits of CBD. In many cases, this is what the cannabis community has been declaring for decades!
We’ll cut to the chase. According to the WHO, CBD is not addictive or toxic. It can be used therapeutically.
Important Findings from the WHO’s CBD Report
The recent report from the WHO is exciting for cannabis users all over the world. What does it say, exactly?
Well, it reveals some important information that people all over the world may want to know. You don’t have to be interested in cannabis to care about this report.
Even if you don’t use cannabis or don’t want to, it’s important to be aware of what changes are occurring in the medical world. As we understand more and more about diseases and possible treatments for them, we can work to alleviate more and more suffering.
The WHO Cannabidiol (CBD) Pre-Review Report from November 2017 says:
“To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD.”
This is a big deal. It gives credence to what the cannabis community has been trying to communicate for quite some time. CBD is perfectly safe and natural, and it has no psycho active effects. It will not get you high, and it is not addictive.
This is a very positive message for those who are suffering and want to try to experience the therapeutic benefits of marijuana but do not desire to get high or stoned.
Plus, this positions CBD as a safe alternative to some other prescription pain management tools. Unfortunately, these tend to come with a high risk of addiction and dependence. In the report, the WHO also says that CBD offers medical benefits without the potential risk of addiction. The report notes:
“In an animal drug discrimination model, CBD failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”
The WHO report says that CBD has “been demonstrated as an effective treatment for epilepsy” in adults, children, and animals. It also includes that there is preliminary evidence that CBD could be beneficial in treating Alzheimer’s disease, cancer, psychosis, Parkinson’s disease, and other conditions.
The fact that this message has been declared by the WHO is a cause for celebration!
Why the WHO is Investigating CBD
Why CBD? Why now? It must be pretty important substance if even the WHO is willing to take notice and spend valuable time and money studying its effects.
According to the Cannabist, WHO has been arranging to examine CBD for a long time.
“At their annual meetings in 2016 and 2015, ECDD (Expert Committee on Drug Dependence) members requested further evaluation of the cannabis plant and its components,” the site reports.
“Last year, the committee set an 18-month timetable to receive additional information and evidence to continue evaluation of cannabis, cannabis extracts and tinctures, delta-9 tetrahydrocannabinol, CBD and THC stereoisomers within the bounds of international drug control policy.”
Prior to this pre review, the ECDD had never formally reviewed cannabis in any way.
However, according to the WHO’s Director-General in the November 25, 2016, recommendations letter, the committee has recognized an increase in the use of cannabis – and its components – for medical purposes, as well as the development of new cannabis related pharmaceutical preparations to be used therapeutically.
This is what led to the willingness to study it. Because it is rising in popularity and so many people are reporting miraculous effects, the WHO was willing to give it some attention, too.
Potential Ramifications of the WHO’s Study
Not surprisingly, the WHO study is making waves with its potential ramifications on the legal and medicinal status of CBD.
Both the WHO and the ECDD, however, have been careful to caution that both of those subjects should be left up to the individual decisions of nations. We are not at a place of worldwide cannabis acceptance yet. However, with steps like this making the news, it seems we’re on the right track!
A major component of the pre review is the WHO’s declaration that CBD should not be a scheduled substance. This should set a standard and send a message to nations like the United States, where cannabis is illegal and banned on a federal level.
With the WHO’s endorsement in place, nations around the world might reconsider how they label the simple marijuana plant.
More Information from the WHO
“At its November 2017 meeting, the WHO Expert Committee on Drug Dependence (ECDD) concluded that, in its pure state, cannabidiol does not appear to have abuse potential or cause harm. As such, as CBD is not currently a scheduled substance in its own right (only as a component of cannabis extracts), current information does not justify a change in this scheduling position and does not justify scheduling of the substance.
“However, where CBD is produced for pharmaceutical purposes as an extract of cannabis, cannabis extracts and tinctures are included in the 1961 UN Single Convention on Narcotic Drugs. A fuller review of extracts or preparations containing almost exclusively CBD will take place in June 2018, when the WHO expert committee will undertake a comprehensive review of cannabis and cannabis related substances.
“Not scheduling a substance means that it is not subject to strict international controls, including for production and supply. Its legal status in countries is something for national legislators to decide. Some countries have eased regulations around cannabidiol, to consider products containing CBD to be medical products. These include Australia, Canada, Switzerland, the United Kingdom, and the United States of America.”
Additional Clarity on the WHO’s Position on CBD
“Saying it should not be scheduled for international control means that it should not be prohibited, at the international level, to produce and supply it for specific purposes, such as medical treatment and research, given that the WHO has not so far seen evidence of potential for abuse or harm from cannabidiol. As to what is legal or illegal, that comes under national law, so it is up to countries to decide.”
This is a big endorsement. Of course the WHO cannot make or change laws for nations individually. They can only make recommendations and share their opinion based on their findings.
Still, by reporting that CBD should not be scheduled for international control shows that they do not consider it a serious threat or a danger to human society as a whole. Other, more harmful drugs, certainly do fit this bill. But CBD does not.
Hopefully, people around the world heard their message loud and clear. CBD is not a threat to the world. It should not be treated like a seriously harmful or deadly controlled substance. They reported that they have not seen evidence of abuse or harm coming from the use of CBD.
Because of this, more and more nations may consider allowing CBD into their own citizens’ lives by easing up on restrictions surrounding CBD.
Not Yet Recommended but Considered for Medical Use
In the same Q&A, WHO explains that while it does not recommend cannabidiol for medical use until there is more evidence,
“Initial evidence from animal and human studies (i.e. a controlled study in the New England Journal of Medicine and other reported individual cases) shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions.”
And, in another ECDD report, the committee said, “There is increased interest from Member States in the use of cannabis for medical indications including for palliative care.”
Clearly, the WHO has interest in exploring CBD for its therapeutic uses. If this is met with more research and evidence, it could spur more countries into changing the legal status of CBD.
This is great news for the cannabis community. As more and more people become accepting, we may start to learn more about what benefits this plant has to offer that we do not even know about yet.
Reactions to the WHO Report
WHO’s report attracted attention from across the world.
Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML), told WebMD:
“It was terrific to see WHO acknowledge what other scientific research has already stated. While we are pleased to see the WHO finally acknowledge that absurdity of international restrictions, the continued domestic classification and criminalization of cannabidiol as a Schedule I controlled substance is out of step with both available science and common sense. It is yet another example of the U.S. government placing ideology over evidence when it comes to issues related to the cannabis plant.”
Raul Elizalde, medical marijuana advocate and hemp-CBD company president, spoke with the EDDC during the November 2017 meeting. Elizade has seen the effects of CBD firsthand, something he shared with the EDDC during the meeting.
“My daughter, Grace, has suffered all her life from epilepsy, and, believe me, I know about psychoactive drugs,” he told the committee. “I have been giving them to her a lot, and I have seen what they do. There’s no comparison with CBD, not even close. It will be a huge mistake to consider CBD psychoactive.”
After the report was released, he told straight.com, “The fact that they don’t want to schedule CBD is something great,” he said. “I think it should be treated the same way as Vitamin C.”
What Comes Next for CBD?
According to the Cannabist, an ECCD meeting is scheduled for May 2018. Committee Secretariat Dilkushi Poovendran told The Cannabist hat the meeting’s “Special Session on Cannabis” will include pre-reviews of cannabis plant and cannabis resin, extracts and tinctures of cannabis, delta-9-Tetrahydrocannabinol (THC), and isomers of THC.
Legally, in the United States, as of May 2017, “federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50 per cent of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use.”
Ideally, with the WHO’s report and its indications, and further exploration into the potential benefits of CBD, its legal status will become clear in the future. With the possible therapeutic uses of CBD in the spotlight on an international scale, we can only hope that more organizations like WHO get involved in bringing these potential advantages to people who need them.
Disclaimer: The Federal Food, Drug and Cosmetic Act requires this disclaimer. We collected this information from various sources for the convenience of our customers. The statements made regarding these products were not evaluated by the Food and Drug Administration. The efficacy of these products is not confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. The information presented here is not meant as a substitute for information from health care practitioners. It is also not meant as an alternative to information from health care practitioners. Before using any product, you should consult your doctor and ask about the risk of interactions or complications.